65,437 trials
Leukemia
Primary: Progression Free Survival (PFS) — 45 Months
Hiatal Hernia
Primary: Number of Subjects With a Hernia Recurrence Requiring Reoperation — 0 Participants
Diabetes Mellitus, Type 1
Primary: Change in Hemoglobin A1c for Usual Care and Tailored Resources (Intervention) Arms, During and Post-Intervention — 0.014; 0.018; 0.035; 0.025 Percent HbA1c per month…
Common Cold
Primary: Number of Participants With One or More Serious Adverse Event(s) (SAEs) — 0; 0; 0 Participants
Contraception
Primary: Number of Participants With Depot Medroxyprogesterone Acetate (DMPA sc) Continuation at One Year by Self-report in Both the Self- and Clinic Administration Arms — 108…
Heart Attack
Primary: Pharmacodynamic Assessment of Degree of Platelet Inhibition as Determined by Verify Now Point of Care Assay and Expressed as P2Y12 Reaction Units (PRU) — 270.23; 247.73…
Urinary Incontinence
Primary: Urinary Continence Recovery — 25; 5 grams
Alcoholism
Primary: Count of Responders and Non-responders in Phase 1 — 103; 80 Participants
Adenocarcinoma of the Prostate · Recurrent Prostate Cancer · Stage I Prostate Cancer
Primary: Number of Patients With Treatment Related GI and/or GU Toxicity as Assessed by the NCI CTCTAE Version 4.0 — 1 Participants
Breast Cancer
Primary: PBMC NF-kB DNA Binding Measured in ng/Well — 9.01; 9.56; 17.54; 16.04 ng/well
Stomach Cancer · Gastric (Stomach) Cancer · Neoplasm of Cardioesophageal Junction
Primary: Progression-Free Survival (PFS) — 9 Participants
Breast Cancer
Primary: Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 90.1; 7.9 percentage of participants
Human Papillomavirus Infection · Stage I Oropharyngeal Squamous Cell Carcinoma · Stage II Oropharyngeal Squamous Cell Carcinoma
Primary: 2-year Loco-regional Tumor Control (LRC) Rate — 100; 93; 96.2 percentage of patients
Supraventricular Tachycardia
Primary: Number of Participants With Freedom From Device-and Procedure-related Adverse Events and Serious Adverse Events — 71; 14; 85; 83 Participants
Chronic Hepatitis C
Primary: Percentage of Participants Achieving Sustained Virologic Response at 12 Weeks (SVR12) Post-treatment — 87.7 percentage of participants